Alnylam Pharmaceuticals (ALNY) Possible Stabilization of Neuropathy Progression, Nanosphere (NSPH) Further Viral Targets on Molecular Tests Posted: October 13, 2014 |
CRWE issued a letter to shareholders from its CEO, Kenneth Bosket. Highlights include: - CRWE's division CRWE-PR has enlarged its web presence with publishing over 1400 community focused, local news and information online sites combined with 10 provinces within Canada. - CRWE has established a joint venture agreement with PolarWeb Media, LLC to drive web traffic and generate revenue from Display Units click-through traffic, by managing and optimizing the CRWE-PR network of websites for monetization to occur as part of its marketing strategy. CRWE will receive 50% of the revenues generated by PolarWeb Media through the use of the company's CRWE-PR sites, with PolarWeb Media having the remaining 50%. - CRWE's letter of intent to acquire 95% of American Video Teleconferencing Corp. (AVOT), remains a great possibility for the company since announcing it on July 2, of this year. AVOT has two divisions: Roxzu (a voucher/coupon distribution mobile app, as well as being a national online business directory) and AVOTube (www.avotube.com) (a video-sharing hosting service that allows users to upload videos to share for exposure, branding, marketing and advertising). - This year, CRWE has regained control of its subsidiary EQCO2, Inc. F/K/A Cleantech Transit, Inc. (CLNO). In the coming months, EQC02, Inc., will get cleaned up and brought current in its filing, as well as having its name changed to "iB2B Global, Inc." iB2B Global, Inc., will become a business to business (B2B) international e-commerce company by providing an efficient, trust worthy on-line and mobile optimized platform to facilitate e-commerce between manufacturers and buyers. - CRWE's operations combined with AVOT and the soon to be renamed to iB2B Global, Inc., shall assist the company in uniquely positioning itself to win in the digital world, with its comprehensive digital network of converged online services and publications.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com **
Transthyretin (TTR)-mediated amyloidosis (ATTR) is an inherited, progressively debilitating, and often fatal disease caused by mutations in the TTR gene. TTR protein is produced primarily in the liver and is normally a carrier of vitamin A. Mutations in TTR cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory neuropathy, autonomic neuropathy, and/or cardiomyopathy. ATTR represents a major unmet medical need with significant morbidity and mortality; familial amyloidotic polyneuropathy (FAP) affects approximately 10,000 people worldwide and familial amyloidotic cardiomyopathy (FAC) is estimated to affect at least 40,000 people worldwide. ALNY reported six-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran (ALN-TTR02), an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP). Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score (mNIS+7) at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics In addition, patisiran treatment achieved a sustained mean serum TTR knockdown at the 80% target level for over nine months, with an up to 89.6% knockdown achieved between doses. Patisiran was found to be generally well tolerated in this study out to one year of therapy. Based on these data, ALNY believes to be evidence for possible stabilization of neuropathy progression after the first six months of treatment, and the potent, rapid, and durable knockdown of TTR achieved by patisiran could be important since TTR protein reduction in patients with ATTR may have the potential to delay or even reverse disease progression with associated clinical benefit.
ALNY is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNA interference is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com. **
The trading levels of NSPH exploded in the right direction on Monday's market activity, after the company said that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Verigene(R) Enteric Pathogens Nucleic Acid Test (EP), which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer. NSPH's Verigene EP is a rapid, easy-to-use and cost-effective alternative to traditional stool diagnostics that the Company believes has the potential to deliver clinical, economic and workflow benefits to hospitals and laboratories. Verigene EP is NSPH's second FDA-cleared test in the area of gastroenteritis, joining the currently marketed Verigene Clostridium difficile Nucleic Acid Test (CDF), which identifies toxigenic C. difficile and differentiates the 027 hypervirulent strain for epidemiological purposes. NSPH's menu includes five multiplex molecular diagnostic tests performed using the automated, sample-to-result Verigene System that target infections of the bloodstream, respiratory tract and gastrointestinal tract. They include the Verigene Gram-Positive Blood Culture Test (BC-GP), the Verigene Gram-Negative Blood Culture Test (BC-GN), the Verigene Respiratory Virus Plus Test (RV+), Verigene CDF (each of which is FDA-cleared and CE-marked), and now Verigene EP. The Verigene System uses NSPH's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. NSPH anticipates CE marking of Verigene EP in early 2015.
NSPH is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. More about Nanosphere, Inc. (NSPH) at www.nanosphere.us. ** Disclaimer: The assembled information disseminated by CRWE-PR Finance is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Crown Equity Holdings Inc. (CRWE) will receive 50% of the revenues generated by PolarWeb Media through the use of CRWE’s sites, with PolarWeb Media having the remaining 50%. Entire Disclaimer at www.finance.crwe-pr.com/disclaimer
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Crown Equity Holdings Inc. (CRWE)
Alnylam Pharmaceuticals, Inc. (ALNY)
Nanosphere, Inc. (NSPH)
